Sonia Nath

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Nutrafol, a leading provider of hair wellness products, on its agreement to sell a majority stake in the company to Unilever. Partner Kevin Cooper led the Cooley team advising Nutrafol on the transaction, and partner Stephane Levy has acted as longtime corporate counsel to the company. Nutrafol is backed by Unilever Ventures and consumer-focused private equity firm L Catterton.

Cooley advised Asymchem, a Chinese-based contract development and manufacturing company serving the global pharmaceutical and biotech industry, on its definitive agreement to acquire Snapdragon Chemistry, a US-based chemical technology company. Partner Yiming Liu led the Cooley team.

As a result of the transaction, Asymchem will significantly expand its footprint in the US, offering customers a seamless path from preclinical process R&D through commercial current good manufacturing practice (cGMP) production. Snapdragon will operate as a stand-alone Asymchem division, and continue with its ongoing lab and manufacturing facility expansion for additional capacity to support larger, pilot-scale manufacturing in Waltham, Massachusetts.

"We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits," Hao Hong, chairman and CEO of Asymchem, said in a news release. "Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool."

Cooley has been representing the Official Committee of Unsecured Creditors of Mallinckrodt during Mallinckrodt’s ongoing bankruptcy proceedings, in which the pharmaceutical company’s Chapter 11 plan of reorganization was recently confirmed after a contentious multiweek trial, marking a defining moment in the case. Cooley partners Cullen Speckhart, Ian Shapiro, Philip Bowman, Michael Klein, Cathy Hershcopf and Jonathan Kim led the team advising the Official Committee of Unsecured Creditors.

Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.